

# EMERGING IMPACT BOND FUND (EIBF)

INVESTING IN INCLUSIVE DEVELOPMENT

## MANAGER'S COMMENT

The Fund recorded a return of 0.31% in the B/C share class in June, ending the month with an investment portfolio of USD 7.1m across 20 direct investees and 17 countries, thus maintaining its broad diversification. While no new investments were made during the month under review, one new investment was approved for disbursement in July.


Through its portfolio, the Fund finances approximately 8,951 end clients, 47% of which are women and 29% of which live in rural areas.

## MARKET COMMENT

While not yet an investee country in the Fund, Myanmar has recently become an investment country in the microfinance industry. The market is still at an early stage, with most microfinance institutions (MFIs) having been incorporated in the last five years, with few (and small) exceptions. Myanmar currently sees high economic growth in excess of 7% p.a. and has a total population of over 50 million, yet more than 70% of the population is estimated not to have any access to financial services. This is explained notably by heavy regulatory constraints, among which the most problematic ones are interest caps on lending and savings rates, making it difficult for MFIs to run profitably. Symbiotics will closely follow developments in this new exciting market that at some point may well become an investment market also for EIBF.

On July 1st India moved to a single indirect tax regime – the Goods and Services Tax (GST), cancelling 17 central, state and local body taxes and thus eliminating inefficiencies in the tax system. The impact on the financial services sector is likely to be limited though tax rates on some bank transactions will increase from 15% to 18%. MSMEs might be impacted but only in the short term.

## PERFORMANCE EIBF B/C USD



## HISTORICAL NET PERFORMANCE (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD
<b>2017</b>	-0.08	0.27	0.74	0.51	0.21	0.31	-	-	-	-	-	-	<b>1.97</b>
<b>2016</b>	-	-	-	-	-	-	-	-	-	-	0.06	-0.23	<b>-0.17</b>

## SHARE CLASS PERF.

	B/C USD
Share Value	1 017.92
Monthly	0.31%
Year-to-date	1.97%
Annualized *	2.70%
Since Inception	1.79%
Best Month	0.74%
Worst Month	-0.23%

\* Since inception

## FUND STATISTICS

Sharpe Ratio	1.51
Annualized Volatility	1.15%
Modified Duration	2.11
3-month US Libor Rate	1.30%

## FUND FACTS

Net Asset Value	USDm 7.9
Investment Portfolio	USDm 7.1
Cash & Liquidities	USDm 0.8
Average Investment	USDm 0.4
Weighted Asset Maturity	27.1 months
Number of Countries	17
Number of Investees	20

## LATEST INVESTMENTS

Abaco, Peru	0.4m
Pan Asia, Sri Lanka	0.3m
KMF, Kazakhstan	0.4m
IBRD, United States	0.5m
HFC Limited, Kenya	0.4m

## IMPACT MEASUREMENT\*

### THEMES

Microfinance	32.6%
SME finance	25.1%
Housing finance	9.4%
Household finance	8.2%
Other	24.6%

### SECTORS

Agriculture	11.6%
Production	4.3%
Trade	27.7%
Services	13.1%
Other	43.3%


### KEY INDICATORS

**8,951** clients (est.)  
**47%** women  
**29%** rural  
**13,849** average financing size (USD)

\* Excluding bonds issued by International Financial Institutions (IFIs).


## FUND COMPOSITION

### ASSET CLASS




\* Promissory Notes

### INVESTEY TYPE




## PORTFOLIO ANALYSIS


### REGION BREAKDOWN (%)




### TOP 10 - COUNTRY BREAKDOWN (%)



### REMAINING MATURITY BREAKDOWN




### CURRENCY BREAKDOWN \*



\*All local currency investments are hedged.


## CREDIT RISK BREAKDOWN

Current Portfolio Credit Risk: **BBB+**



## COUNTRY RISK BREAKDOWN

Current Portfolio Country Risk: **BBB-**



Source: Internal Symbiotics Methodology.

## LEGAL DISCLAIMER

The fund is domiciled in Luxembourg and has not been approved for distribution to non qualified investors in or from Switzerland by the Swiss Financial Market Supervisory Authority (FINMA) pursuant to the Swiss Collective Investment Schemes Act of 23 June 2006 (the "CISA") and its implementing regulations. Accordingly, the fund offered hereby may only be offered and this document may only be distributed in or from Switzerland to qualified investors (as such term is defined in the CISA and its implementing regulations). This document and any other materials relating to the fund may only be used by those qualified investors to whom it has been handed out in connection with the offer described herein. It may not be copied, used by, distributed or made available to any other person. Past performance should not be taken as an indication or guarantee of future performance and no representation or warranty, expressed or implied, is made by Symbiotics SA regarding future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units. CACEIS (Switzerland) SA, whose registered office is at Route de Signy 35, 1260 Nyon, Switzerland acts as the Swiss Representative Agent (the "Representative") of the fund. CACEIS Bank Luxembourg, Luxembourg, succursale de Nyon whose registered office is at 35, Route de Signy, CH-1260 Nyon acts as the Swiss Paying Agent of the fund. Only the latest version of the fund's prospectus, regulations and annual reports may be relied upon as fund the basis for investment decisions. These documents are available free of charges at the Representative's offices. The place of jurisdiction of the Representative is Switzerland. Symbiotics SA, Rue de la Synagogue 31, 1204 Geneva, Switzerland; Phone: +41 (0)22 338 15 40; symbioticsgroup.com; [1]info@symbioticsgroup.com | Factsheet #438

Past performance should not be taken as an indication or guarantee of future performance and no representation or warranty, expressed or implied, is made by Symbiotics SA regarding future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units.